Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic … Read more
Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) - Net Assets
Latest net assets as of June 2025: CN¥1.83 Billion CNY
Based on the latest financial reports, Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) has net assets worth CN¥1.83 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.12 Billion) and total liabilities (CN¥1.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.83 Billion |
| % of Total Assets | 58.74% |
| Annual Growth Rate | 89.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4493.02 |
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Net Assets Trend (2021–2024)
This chart illustrates how Chongqing Genrix Biopharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chongqing Genrix Biopharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual net assets of Chongqing Genrix Biopharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.13 Billion | -23.64% |
| 2023-12-31 | CN¥2.78 Billion | +9473.79% |
| 2022-12-31 | CN¥29.08 Million | -90.68% |
| 2021-12-31 | CN¥311.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chongqing Genrix Biopharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 217495859935.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥4.54 Billion | 213.72% |
| Total Equity | CN¥2.13 Billion | 100.00% |
Chongqing Genrix Biopharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Chongqing Genrix Biopharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
$413.85 Million |
|
Logility Supply Chain Solutions, Inc.
NASDAQ:LGTY
|
$413.85 Million |
|
PT Sarana Menara
JK:TOWR
|
$413.86 Million |
|
Grape King Bio Ltd
TW:1707
|
$413.97 Million |
|
Fuller Smith & Turner P.L.C
PINK:FTUAF
|
$413.74 Million |
|
China Motor Corp
TW:2204
|
$413.67 Million |
|
Alarko Holding AS
IS:ALARK
|
$413.66 Million |
|
Hanjaya Mandala Sampoerna Tbk PT
JK:HMSP
|
$413.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongqing Genrix Biopharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,784,232,358 to 2,126,042,788, a change of -658,189,571 (-23.6%).
- Net loss of 797,273,630 reduced equity.
- Dividend payments of 28,668,205 reduced retained earnings.
- Other factors increased equity by 167,752,264.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-797.27 Million | -37.5% |
| Dividends Paid | CN¥28.67 Million | -1.35% |
| Other Changes | CN¥167.75 Million | +7.89% |
| Total Change | CN¥- | -23.64% |
Book Value vs Market Value Analysis
This analysis compares Chongqing Genrix Biopharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.54x to 4.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥1.13 | CN¥26.70 | x |
| 2022-12-31 | CN¥0.11 | CN¥26.70 | x |
| 2023-12-31 | CN¥7.59 | CN¥26.70 | x |
| 2024-12-31 | CN¥5.80 | CN¥26.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongqing Genrix Biopharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2649.19%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.48x
- Recent ROE (-37.50%) is above the historical average (-537.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -103.26% | -821.97% | 0.04x | 3.21x | CN¥-353.33 Million |
| 2022 | -1981.88% | -121278.62% | 0.00x | 33.08x | CN¥-579.27 Million |
| 2023 | -28.78% | -66142.61% | 0.00x | 1.29x | CN¥-1.08 Billion |
| 2024 | -37.50% | -2649.19% | 0.01x | 1.48x | CN¥-1.01 Billion |
Industry Comparison
This section compares Chongqing Genrix Biopharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) | CN¥1.83 Billion | -103.26% | 0.70x | $413.83 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |